• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

BMS, Kereos collaborate on imaging agents

Article

Bristol-Myers Squibb Medical Imaging and Kereos have agreed to partner in the development and commercialization of novel molecular imaging agents. The goal is to develop agents that will detect disease on a molecular level, potentially enabling earlier

Bristol-Myers Squibb Medical Imaging and Kereos have agreed to partner in the development and commercialization of novel molecular imaging agents. The goal is to develop agents that will detect disease on a molecular level, potentially enabling earlier and more effective diagnosis and highly targeted treatment of cardiovascular diseases and cancer. The companies will work together to develop molecular imaging agents using Kereos' core technology. BMS Medical Imaging has obtained exclusive worldwide rights to develop and commercialize select cardiovascular molecular imaging agents for MR. Kereos has obtained exclusive worldwide rights to use a family of BMS targeting molecules with Kereos' core technology to develop and commercialize imaging agents and targeted therapeutics. These include KI-001, Kereos' lead candidate for early MR detection of tumors. In addition to working with BMS, Kereos is collaborating with Philips Medical Systems for the development of molecular imaging systems.

Related Videos
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.